Global Pleural Disease Therapeutics Market Set to Surpass USD 9.4 Billion by 2033 a steady CAGR of 6.5%: Future Market Insights Report

The global pleural disease therapeutics market is poised for significant growth, with a projected valuation of USD 9.4 billion by 2033, according to a recently published study by Future Market Insights. Registering a steady CAGR of 6.5% over the next decade, the market is expected to rise from USD 4.98 billion in 2023.

This growth is driven by the increasing prevalence of critical health conditions such as congestive heart failure, lung diseases, pneumonia, cancer, and tuberculosis. As these conditions often lead to pleural effusion—a buildup of fluid in the pleural cavity—the demand for effective treatments and diagnostics is escalating worldwide. Delayed diagnosis of pleural effusion can lead to severe morbidity and mortality, underscoring the urgent need for advanced therapeutic procedures.

Key Drivers of Market Growth:

  1. Rising Incidence of Pleural Effusion-Related Diseases:

Conditions such as systemic lupus erythematosus (30%-50% of patients) and idiopathic pulmonary hypertension (21.5% of patients) exhibit a high association with pleural effusion. This surge in cases is expected to bolster demand for pleural disease therapeutics globally.

  1. Advancements in Diagnosis and Expertise:

Enhanced diagnostic techniques and the availability of skilled healthcare professionals specializing in pleural effusion treatment are pivotal in driving market expansion.

  1. Innovative Product Launches and Strategic Developments:

Leading market players are investing heavily in R&D and strategic collaborations. For instance, in September 2021, BDR Pharma introduced BIAPENEM, a groundbreaking therapeutic solution for treating intra-abdominal infections, lower respiratory infections, and complex urinary tract infections. The drug’s efficacy in penetrating lung tissues and body fluids such as pleural effusion has positioned it as a vital innovation in pleural disease therapeutics.

Future Outlook:

The increasing focus on early diagnosis and innovative treatment solutions is expected to sustain the momentum of the Pleural Disease Therapeutics Market over the forecast period. Additionally, ongoing investments, mergers, and product launches by key industry players will further accelerate market growth.

As healthcare systems worldwide prioritize addressing critical respiratory and cardiac conditions, the demand for advanced pleural disease therapeutics is anticipated to remain robust, positioning this market as a vital component of global healthcare advancements.

Rising Interest in Market Trends: Our Detailed Report Provides Essential Insights!

Key Takeaways from the Market Study:

  • North America is expected to dominate the industry while reaching market share of around 45% by end of the forecast period
  • The market in Europe is projected to account for 29% market share during the projected timeline
  • By treatment type, thoracentesis is projected to account for 34% market share by end of the forecast period
  • Hospitals are expected to dominate the market by end-user, with a market share of 65 % by 2033
  • Global market for pleural disease therapeutics to reach USD 4.98 billion by the end of 2023

“Adoption of novel drugs and mergers and acquisitions between companies are going to positively influence market of Pleural disease therapeutics during the forecast period,” comments an FMI analyst.

Competitive Landscape:

The Pleural diseases therapeutics market is moderately competitive and consists of various key market players. These players are creating novel delivery systems for treating Pleural diseases. This is anticipated to fuel Pleural diseases therapeutics market. The key players in the market are: WakeMed Health and Hospitals, Boston Medical, Max Healthcare, Avik Pharma, Pfizer CentreOne, Hovione, Pipelinepharma, Hoffmann-La Roche AG, Boehringer Ingelheim International GmbH, Bausch Health Companies Inc., Sanofi S.A.

Key market players are focusing on adoption of inorganic growth strategies such as acquisition, partnerships, and collaboration in order to enhance their product portfolio. This is expected to propel the global Pleural diseases therapeutics market.

  • In September 2021, Bristol Mayer Squibb announced three-year data from the Checkmate -743 trial. According to the clinical trial data, serious adverse reactions occurred in almost 54% of patients receiving OPDIVO plus YERVOY. The most frequent serious adverse reactions reported in ≥2% of patients were pneumonia, pyrexia, diarrhea, pneumonitis, pleural effusion, dyspnea, acute kidney injury, infusion-related reaction, musculoskeletal pain, and pulmonary embolism.
  • In January 2020, Argon Medical launched single and triple loop retrieval kits for its U.S. market with the aim to improve lives of patients. The products have managed to secure the approval from the United States Food and Drug Administration, and are efficient in the removal of retrievable IVC filters with the help of a jugular approach. These single and triple loop retrieval kits are the only 2 kits to have received FDA approval in terms of any retrievable IVC filter from a jugular approach.

Key Segments Profiled in the Pleural Diseases Therapeutics Industry Survey:

By Treatment:

  • Drug Class
    • Antibiotics
    • Antifungals
    • Corticosteroids
    • Narcotic Analgesics
    • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Bullectomy
  • Chemotherapy
  • Video-Assisted Thorascopic Surgery (VATS)
  • PleurX Catheter
  • Pleurodesis Therapy
  • Radiation Therapy
  • Thoracentesis
  • Thoracostomy

By End Users:

  • Hospitals
  • Specialty Clinics
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Molecular Spectroscopy Market to Reach USD 12.87 Billion by 2033 CAGR of 7.2% | FMI

The global molecular spectroscopy market is poised for substantial growth, with projections indicating it will reach a valuation of USD 12.87 billion by 2033, up from USD 6.42 billion in 2023, at a robust Compound Annual Growth Rate (CAGR) of 7.2%. This upward trend is largely fueled by the increasing adoption of advanced analytical technologies in the pharmaceutical sector.

Molecular spectroscopy has become indispensable to pharmaceutical research and development, offering crucial insights into material composition, structure, and properties at a microscopic level. This analytical capability strengthens the reliability and safety standards of pharmaceutical products, a critical factor as the industry navigates stringent regulatory demands.

The molecular spectroscopy market includes several essential techniques, such as UV-Visible, Infrared (IR), Raman, and Nuclear Magnetic Resonance (NMR) spectroscopy. These methodologies play a key role in pharmaceutical R&D, enabling precise identification and characterization of molecules critical to drug discovery, quality control, and regulatory compliance.

Further boosting the market’s growth is the advancement of spectroscopic instruments and the expansion of applications in areas beyond pharmaceuticals, including drug discovery, forensic analysis, and quality control. The global prevalence of chronic diseases also underscores the importance of accurate molecular analysis in healthcare diagnostics, driving demand for these technologies across the healthcare spectrum.

As applications for molecular spectroscopy continue to expand, the industry is set to experience dynamic growth, with the technology cementing its place as a fundamental tool in pharmaceutical and healthcare diagnostics worldwide.

Key Takeaways from the Molecular Spectroscopy Market Report:

  • The molecular spectroscopy market is expected to grow at a CAGR of 7.2% from 2023 to 2033.
  • Nuclear Magnetic Resonance spectroscopy dominates the global market with an overall revenue share of 32.40%.
  • The United States of America is the largest consumer of molecular spectroscopy, with a revenue share of 35.8%.
  • China is leading the molecular spectroscopy market growth with a CAGR of 12.3% through 2033. It is followed by South Korea (9.7%), India (8.8%), and Japan (8.5%).
  • The pharma industry is the largest consumer of molecular spectroscopy technology, with a global share of 34.70% of the market by type.

“Heavy initial monetary investments and a skilled workforce are required to interpret the complex data generated by techniques like molecular spectroscopy. Successfully overcoming these two challenges in the market can open doors for several breakthroughs in fields such as pharmaceuticals, materials science, and environmental monitoring”, opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI) analyst.

Interest in Market Trends: Get Detailed Analysis and Insights with Our Comprehensive Report!

Competition Analysis:

The revenue growth for the molecular spectroscopy market is heavily dependent on the technological advancements in the medicare and pharmaceutical industry. As more industries become familiar with the capabilities and applications of this technology, its adoption is likely to expand across diverse sectors. This will fuel the growth of the molecular spectroscopy market and contribute to advancements in diagnostics, drug development, materials science, and environmental monitoring.

Key Companies in the Molecular Spectroscopy Market:

  • Renishaw
  • JEOL
  • Hitachi High-Tech Science
  • Nikon
  • Olympus
  • Agilent Technologies
  • PerkinElmer
  • Andor
  • Hamamatsu Photonics
  • Keyence
  • Lasertec
  • Prometec

Key Developments in the Molecular Spectroscopy Market:

  • Horiba has recently introduced an advanced confocal Raman microscope, allowing researchers to study the real-time dynamics of molecules and chemical reactions.
  • WITec has developed an innovative scanning probe microscope tailored for tip-enhanced Raman spectroscopy (TERS). TERS is a technique that significantly enhances the Raman signal of molecules, amplifying it by up to 10^6 times and enabling Raman spectroscopy at spatial resolutions as fine as 10 nm.
  • Oxford Instruments has developed a new X-ray photoelectron spectrometer (XPS) that can perform XPS analysis on samples in their native environment. This eliminates the need to prepare samples for XPS analysis, which can damage or alter the selection.
  • Bruker Corporation introduced an innovative Raman microscope capable of achieving 3D imaging of samples with sub-wavelength resolution. This microscope employs a distinctive optical system to concentrate the Raman signal onto a detector, yielding high-resolution images with minimal interference.
  • Thermo Fisher Scientific unveiled a novel scanning electron microscope (SEM) that enables correlative microscopy with Raman spectroscopy. This integration allows researchers to examine the same sample area using SEM and Raman spectroscopy, providing complementary insights into the sample’s structure and composition.

Key Segments:

By Type:

  • Infrared Spectroscopy
  • Nuclear Magnetic Resonance (NMR) Spectroscopy
  • Color Measurement Spectroscopy
  • Raman Spectroscopy
  • Near-Infrared (NIR) Spectroscopy
  • Ultraviolet-visible (UV-Vis) Spectroscopy

By Application:

  • Research Institutes
  • Food and Beverages Testing
  • Pharmaceuticals
  • Environmental Testing
  • Biotech
  • Others

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • Europe
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global IV Disposables Market Set for Remarkable Growth 11.8% CAGR, Reaching USD 51.6 Billion by 2033

The global IV disposables market is on the cusp of significant expansion, with Future Market Insights projecting a robust compound annual growth rate (CAGR) of 11.8% from 2023 to 2033. The market, currently valued at USD 17.0 billion in 2023, is expected to reach an impressive USD 51.6 billion by 2033.

This forecasted growth follows a strong performance in recent years, with the market recording a valuation of USD 15.5 billion in 2022. This marks a notable year-over-year growth of 9.6% leading into 2023, highlighting the increasing demand for IV disposables across diverse healthcare settings.

The escalating demand is largely attributed to the widespread utilization of infusion pumps and related accessories in medical facilities as well as home care settings. IV disposables play a crucial role in delivering vital medications, fluids, and nutrients to patients, driving their adoption across the healthcare landscape.

“The market’s steady expansion reflects the increasing reliance on IV disposables for efficient and safe delivery of treatments in healthcare facilities worldwide,” stated a Future Market Insights. “With advancements in medical technology and a growing emphasis on patient-centric care, the demand for IV disposables is expected to continue its upward trajectory in the coming years.”

Key market players are anticipated to leverage this growth opportunity by focusing on product innovation, strategic collaborations, and expanding their geographical presence. By catering to evolving healthcare needs and ensuring product quality and reliability can position themselves to capitalize on the burgeoning demand for IV disposables.

To Put It Concisely, The Takeaway Is IV Disposables Market:

  • By Product, Infusion pumps are the leading segment as and held about 48.1% market share in 2022, due to efficiency, accuracy, and versatility in delivering fluids and medications in various healthcare settings.
  • By End User, the hospitals dominated the global IV disposables market withholding the total market share of about 54.6% by the end of 2022, as they offer specialized treatment options that require advanced IV therapies.
  • By Region, North America is leading in the global IV disposables market and is expected to continue to do so with a projected CAGR rate of 10.6% during the forecasted years, due to increasing prevalence of chronic diseases in the region.

Accelerated Market Demand: Find Comprehensive Insights and Trends in Our Full Report!

Potential Elements That Might Limit the Expansion of the IV Disposables Market:

  • The IV disposables market is subject to stringent regulations to ensure patient safety and product quality. Changes in regulatory requirements or delays in obtaining approvals for new products can hinder market growth.
  • Healthcare providers, especially in cost-sensitive environments, might exert pressure to reduce the cost of IV disposables. This can lead to manufacturers facing challenges in maintaining profitability while keeping prices competitive.
  • The IV disposables market can become saturated with multiple manufacturers offering similar products. Intense competition can lead to price wars and reduced profit margins, making it challenging for companies to expand and invest in research and development.
  • Rapid advancements in medical technology could lead to the development of alternative treatment methods that reduce the reliance on traditional IV therapies, impacting the demand for IV disposables.

Key Companies Profiled:

  • B. Braun Melsungen AG
  • Baxter
  • 3M
  • Terumo Corporation
  • Nipro Corporation
  • Teleflex Incorporated
  • Becton, Dickinson and Company
  • Smiths Medical/ICU Medical
  • Moog Inc
  • AngioDynamics.
  • Fresenius SE & Co. KgaA
  • arcomed ag

Key Segments Covered in IV Disposables Market Industry Research:

By Product:

  • Intravenous Administration Set
  • IV Fluid Solution Bags
  • IV Cannula
  • Infusion Sets
  • Infusion Pumps
  • Catheter Needles
  • Securement Devices
  • Others (Stopcocks, connectors, Extention Tubes)

By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Home Care Settings

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Gingivitis Treatment Market reaching USD 11.19 Billion by 2033 at a CAGR of 4.8%

The global gingivitis treatment market is worth USD 7 Billion as of now and expected to reach USD 11.19 Billion by the year 2033 at a CAGR of 4.8% between 2023 and 2033.

The end-consumers are turning out to be all the more conscious regarding an inseparable link between health on the whole and oral health; thereby resulting in an ever-increasing demand for oral care services as well as products.

Also, there is a tremendous rise in the number of online sales channels, which foster the growth further. With gum diseases growing in frequency, there is no stoppage to the gingivitis treatment market.

Gingivitis causes bleeding and inflammation of gums. Moreover, if not treated on time, it could progress to all the more severe form of gum disease. The WHO states that gingivitis affects close to 90% of the population worldwide.

Poor oral hygiene, aging, smoking, chewing of tobacco result in gingivitis. However, the good part is that awareness in this regard is rising. As such, apart from drugs, lasers are getting used for treating the disease. This factor is expected to enhance the popularity of gingivitis treatment market going forward.

At the same time, the fact that gingivitis treatment is costly could hamper the gingivitis treatment market going forward. Also, compliance to regulations in this regard is challenging. So, small companies may have to think twice before venturing herein.

Future Market Insights has entailed these facts with future prospects in its latest market study entitled ‘Gingivitis Treatment Market’. It has its team of analysts and consultants to execute using an eagle’s eye view in its primary, secondary, and tertiary modes of research.

“With growing awareness regarding oral hygiene, the global gingivitis treatment market is expected to go great guns in the forecast period”, says an analyst from Future Market Insights.

Competitive Treatment:

  • It was announced in October 2022 that rapid test regarding gum disease was being developed at the University of Birmingham. The basic purpose of this probe is that of being used in point-of-care settings like dental pharmacies or surgeries. It could also help in detection of lung or heart disease at an early stage, along with rheumatoid arthritis and type 2 diabetes. On these grounds, Professor Tim Albrecht from School of Chemistry and Dr. Melissa Grant from the School of Dentistry at the University have developed a unique technique of precise assessment of gum disease using sample of saliva.
  • The other players in gingivitis treatment market include Fibrocell Sciences, Eli Lilly & Company, Dentsply International, Align technology, Ultradent Products Inc., 3M Company, Glidewell Laboratories, Nobel Biocare Holdings AG, Kaken Pharmaceutical, Orapharma, and Valeant Pharmaceuticals Inc. They are engaging in various modes of expansion like new product launch, mergers, acquisitions, partnerships, and joint ventures to make a mark for themselves in gingivitis treatment market.

Heightened Market Interest: Our Complete Report Delivers Extensive Analysis and Trends!

What does the Report say?

  • The research study is based on drug class (veetids, erythrocin, minocycline, doxycycline, clindamycin, chlorhexidine, acetaminophen, ibuprofen, and lidocaine), route of administration (oral and topical), and end-user (hospital pharmacy, retail pharmacy, and online pharmacy).
  • With growing prevalence of gum disease, the global gingivitis treatment market is expected to grow irresistibly in the forecast period.

Key Companies Profiled:

Fibrocell Sciences, Tolmar Inc., Eli Lilly & Company, Align Technology, Dentsply International, 3M Company, Ultradent Products Inc., Nobel Biocare Holdings AG, Glidewell Laboratories, Orapharma, Kaken Pharmaceutical, and Valeant Pharmaceuticals Int.

Key Segments Profiled in the Gingivitis Treatment Industry Survey:

Drug Class:

  • Veetids
  • Erythrocin
  • Minocycline
  • Doxycycline
  • Clindamycin
  • Chlorhexidine
  • Acetaminophen
  • Ibuprofen
  • Lidocaine

Route of Administration:

  • Oral
  • Topical

End-User:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Dengue Vaccines Market Poised for Significant Growth, Projected to Reach USD 1,603.7 million by 2033: FMI Report

The global dengue vaccines market is set for significant expansion, with total revenue expected to exceed USD 474.8 million by 2023. Projections indicate that the market will soar to USD 1,603.7 million by 2033, driven by an impressive compound annual growth rate (CAGR) of 12.9% by volume.

This surge in demand is propelled by several key factors, including groundbreaking advancements in dengue vaccine development. Leading pharmaceutical companies are nearing the completion of major clinical trials, with results expected to reshape the landscape of dengue vaccine availability. As a result, the dominance of the current vaccine, Denvaxia®, is anticipated to give way to a range of new alternatives, enhancing treatment options for this global health threat.

The growth of the dengue vaccines market is also being fueled by a series of international collaborations and partnerships between healthcare stakeholders from diverse institutional settings. These collaborations are spurring the development of novel vaccine formulations, with clinical trials and research intensifying. A significant portion of this growth is expected to occur in the Asia-Pacific region, home to the highest concentration of dengue fever cases and a strong presence of reputable regional pharmaceutical companies.

While a large percentage of dengue cases are asymptomatic, moderate, or self-managed, the true scale of the infection is often under-reported. Estimates suggest that there are 390 million dengue virus infections annually, with 96 million presenting clinically. This underreporting further underscores the critical need for effective vaccination solutions.

India, in particular, is witnessing a remarkable shift in its dengue vaccination market, supported by national expert groups and collaborative efforts between various healthcare organizations. These initiatives are helping to accelerate research and development in vaccine technology, positioning India as a key player in the global market. With increasing awareness and collaboration, India is expected to play a pivotal role in boosting the growth prospects of the dengue vaccines market in the coming years.

As the global fight against dengue intensifies, the market for dengue vaccines is poised for continued innovation and growth, promising improved prevention strategies and a brighter future for the millions affected by this disease worldwide.

Key Takeaway:

  • Over the historical period, the worldwide market grew at an 11.9% CAGR.
  • Over the next several decades, the Chinese market is expected to grow at a CAGR of 14.8%.
  • The United States has emerged as a key market, accounting for more than 16.5% of overall demand in 2022.
  • The Indian market is expected to grow at a CAGR of 11.7% in the future decades.
  • In 2022, the Government Institutes category had a market share of Government Institutes.

“As a result the worldwide dengue fever prevalence burden is mostly concentrated in Asian nations, major pharmaceutical businesses are projected to discover lucrative income streams in India, Japan, and South East Asia.” says an FMI analyst.

Growing Need for Market Insights: Access Our Full Report for Thorough Analysis and Trends!

Competitive Landscape:

The renowned firms’ primary expansion strategy remains clinical trials to create several vaccine candidates. Market participants are effectively exploiting strategic collaborations with big pharmaceutical businesses or research institutions, mergers and acquisitions, and capacity expansion projects to accomplish this.

  • Takeda revealed in May 2023 that their dengue vaccine QDENGA® has gained various authorizations, which includes one from Brazil’s National Health Surveillance Agency in March 2023 for use in persons aged 4 to 60 years to safeguard against all four serotypes.
  • Argentine health officials have approved the application of a Japanese dengue vaccine that must be provided in two doses three months distant, according to a story in Buenos Aires in April 2023.

Key Companies Profiled:

  • Sanofi Pasteur Limited
  • Takeda Pharmaceutical Company Limited
  • Merck & Co. Inc.
  • GlaxoSmithKline Plc.
  • GeneOne Life Science Inc.
  • Medigen Vaccine Biologics Corporation
  • Panacea Biotec Limited
  • Sun Pharmaceutical Industries Ltd
  • Serum Institute of India Pvt. Ltd.
  • Biological E Ltd.

Key Segments Covered

Product:

  • CYD-TDV (Dengvaxia)

End-User:

  • Hospitals
  • Government Institutes
  • Non-governmental Organizations (NGOs)

Region:

  • North America (USA and Canada)
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Congenital Adrenal Hyperplasia Treatment Market Set for Significant Growth, Projected to Reach USD 892 Million by 2033

The global congenital adrenal hyperplasia treatment market is poised for substantial expansion, with a projected Compound Annual Growth Rate (CAGR) of 8.1% from 2023 to 2033, as per a recent report by Future Market Insights. The market, valued at USD 409.36 million in 2023, is forecasted to soar to USD 892 million by 2033.

Several factors contribute to this surge in market growth, including heightened awareness of the ailment, advancements in diagnosis and screening technologies, and remarkable progress in medical research and development.

Congenital adrenal hyperplasia (CAH) is a genetic disorder that affects the adrenal glands, leading to inadequate production of cortisol and aldosterone. As awareness about CAH increases, there has been a corresponding rise in demand for effective treatments, thereby propelling market growth.

Furthermore, advancements in diagnosis and screening technologies have facilitated early detection and intervention, enabling healthcare professionals to provide timely and targeted treatments to patients with CAH. This has not only improved patient outcomes but has also driven market expansion.

Moreover, significant strides in medical research and development have led to the introduction of innovative treatment options for CAH, offering patients improved therapeutic efficacy and better quality of life.

The projected growth of the CAH treatment market highlights a significant opportunity for pharmaceutical companies, healthcare providers, and other stakeholders to collaborate in addressing the unmet needs of patients with this rare genetic disorder.

Key Takeaways from the Market Study:

  • The Congenital Adrenal Hyperplasia treatment market is expected to grow at a value of 8.1% CAGR for the forecast period 2023 to 2033.
  • By treatment, Mediation is expected to hold 43% of the market share in 2023 for Congenital Adrenal Hyperplasia treatment market.
  • North America is expected to possess 45% market share for Congenital Adrenal Hyperplasia treatment market in 2023.
  • Europe Congenital Adrenal Hyperplasia treatment market size is expected to possess 40% market share in 2023.

“There are several treatment options available for CAH, which can help to manage symptoms and improve overall quality of life. In addition, the invention of diagnostic tools too is favoring the growth of the market.” states an FMI analyst

Surge in Market Demand: Explore Comprehensive Trends and Analysis in Our Full Report!

Competitive Landscape:

Key players in the Congenital Adrenal Hyperplasia treatment are Neurocrine Biosciences, Diurnal Limited, Spruce Biosciences, Adrenas Therapeutics, Millendo Therapeutics, Emerge Health, Thermo Fisher Scientific, Adrenas Therapeutics, Inc., Alder Biopharmaceuticals, Inc and Zydus Lifesciences Ltd.

  • Spruce Biosciences is a pharmaceutical company that is developing a medication called tildacerfont for the treatment of Congenital Adrenal Hyperplasia (CAH). Tildacerfont is a selective oral antagonist of the corticotropin-releasing hormone receptor 1 (CRH-R1) that is designed to reduce the overproduction of androgens in patients with CAH.
  • Millendo Therapeutics lead product candidate for CAH is called livoletide, which is a synthetic analogue of the neuropeptide alpha-melanocyte-stimulating hormone (α-MSH). Livoletide is designed to target the melanocortin-4 receptor (MC4R) in the brain, which plays a key role in regulating the production of adrenal androgens.

Key Segments Profiled in the Congenital Adrenal Hyperplasia Treatment Survey:

Type:

  • Classic Congenital Adrenal Hyperplasia
  • Non-classic Congenital Adrenal Hyperplasia

Treatment:

  • Medication
  • Hormone Replacement Therapy
  • Corticosteroid
  • Glucocorticoids
  • Salt Supplements
  • Others
  • Surgery

End-user:

  • Hospitals
  • Pharmacies
  • Specialty Clinics

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:          

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Increase in Cardiovascular Disorders, Combined with Advances in Diagnostic Procedures, is Boosting Demand for Cardiovascular Diagnostic Products, Resulting in a Robust Industry: Future Market Insights

The global cardiovascular diagnostics market is expected to grow at a significant rate in the coming years, driven by several factors including increasing rising tobacco consumption around globe. The increase cardiovascular diseases (CVD) globally, will drive the global market from USD 5.9 Billion in 2023, to USD 9.7 Billion by the end of 2033. The market is projected to expand at a CAGR of 5.1% over the forecast period (2023-2033).

The global market for cardiovascular diagnostics is expanding rapidly due to a variety of causes. The increased prevalence of cardiovascular disorders, developments in diagnostic techniques such as electrocardiogram (ECG), and rising demand for quick and simple diagnostic tests are propelling the market forward.

By developing new imaging technologies, portable diagnostic gadgets, and molecular diagnostic techniques, manufacturers can innovate and improve patient care. Furthermore, the use of data analytics and AI algorithms improves diagnostic accuracy and clinical decision-making. However, problems such as a shortage of skilled staff, budgetary constraints, and insufficient regulations and policies are limiting market expansion.

The market experienced growth in 2021, surpassing initial projections before the COVID-19 pandemic. Since the emergence of COVID-19 three years ago, over 750 million individuals worldwide have been affected by the disease. Recent studies have indicated that certain individuals who have contracted COVID-19 are at a higher risk of developing cardiovascular conditions like irregular heartbeat, stroke, and heart failure.

The connection between COVID-19 and cardiovascular disease has been observed, highlighting the potential long-term impact of the virus on cardiovascular health. This correlation emphasizes the importance of addressing and monitoring the cardiovascular health of individuals who have had COVID-19, as well as the need for continued research and advancements in cardiovascular diagnostics and treatments to mitigate the potential consequences of the disease. Overall, the cardiovascular diagnostic market is likely to expand in the next years, offering a cost-effective and simple option for patients suffering from CVDs.

Key Takeaways from Market Study:

  • Electrocardiogram (ECG) systems holds a significant market share of 4% in the global cardiovascular diagnostics market in 2022 due to prominence of ECG systems globally.
  • Hospitals take away the larger share among all end user due to availability of most of diagnostic products and equipment in the hospitals. The segment held around 5% value share in 2022.
  • The North America region accounts for the dominant market share at 4%, with a market value of USD 2.1 Billion in 2022 owed to strong market presence of key players in North America contributing to the overall advancement and expansion of the cardiovascular diagnostics market.

“The increasing global prevalence of cardiovascular disease has led to a growing demand for CVD diagnostics in recent years, this presents a favourable opportunity for entry into the cardiovascular disease diagnostic market.” says an analyst of Future Market Insights.

Rising Demand for Market Data: Our Full Report Offers Deep Insights and Trend Analysis!

Market Competition:

The cardiovascular diagnostic industry is extremely competitive, with GE Healthcare and Abbott Laboratories among the leading participants. To achieve a greater market share, these firms are continually reinventing their goods and marketing techniques, with an emphasis on price, convenience, and efficacy.

  • In February 2023, GE HealthCare aims to revolutionize ultrasounds by making them accessible worldwide, as demonstrated by their recent acquisition of Caption Health, an AI software company specializing in cardiac imaging.
  • In September 2022, SRL Diagnostics introduces ‘Heart Assure’, a specialized blood test using high sensitivity Troponin I to accurately predict the risk of cardiac events.

Key Companies Profiled:

  • Medtronic plc
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Biotronik SE & Co. KG
  • Schiller, Koninklijke Philips N.V.
  • GE Healthcare and Wayra
  • Siemens Healthcare
  • Lepu Medical
  • Midmark Corp
  • Roche Ltd
  • Randox Laboratories Ltd.
  • Robonik India
  • Diasorin
  • Elabscience Biotechnology

Key Market Segments Covered in the Cardiovascular Diagnostics Industry Research:

By Product:

  • Electrocardiogram (ECG) system
  • Resting ECG Systems
  • Cardiopulmonary Stress Testing Systems
  • Holter Monitoring Devices
  • Event Monitoring Devices
  • Implantable Loop Recorder (ILR)
  • Others

By Point-of-Care Testing:

  • Analyzers
  • Lipoprotein Test Kits
  • Angiotensin Test Kits
  • Fibrinogen Test Kits
  • Serum Uric Acid Test Kits
  • High-Sensitivity CRP (hs-CRP) Kits

By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Cardiac Catheterization Labs
  • Diagnostic Imaging Centers

By Region:

  • North America
  • Latin America
  • East Asia
  • South Asia & Pacific
  • Europe
  • Central Asia
  • Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Chronic Brain Damage Management Market Set to reach Projected to Reach USD 1.77 Billion by 2033, Driven by Accelerating Demand for Advanced Solutions | FMI

Future Market Insights (FMI) has unveiled a pioneering market analysis indicating that the global chronic brain damage management market is on track for remarkable growth over the next decade. Valued at USD 0.9 billion in 2023, the market is projected to nearly double, reaching USD 1.77 billion by 2033. This impressive expansion reflects a robust compound annual growth rate (CAGR) of 7%, a substantial increase from the 3.5% CAGR recorded between 2018 and 2022.

This surge in market growth underscores a significant shift in the demand for advanced solutions in managing chronic brain injuries and neurological disorders. The escalating global incidence of conditions such as stroke, traumatic brain injury, and cerebral palsy is a major driver of this growth. The World Health Organization (WHO) reports that strokes affect approximately 15 million people annually, while traumatic brain injuries impact an estimated 69 million individuals each year. This alarming prevalence highlights the urgent need for innovative therapies and comprehensive management strategies.

As the global population ages and lifestyle factors evolve, the demand for effective chronic brain injury management is anticipated to increase even further. This presents a significant opportunity for industry stakeholders to develop and introduce groundbreaking solutions aimed at improving patient outcomes and enhancing quality of life.

The increased pace of market expansion reflects the global healthcare community’s commitment to advancing the diagnosis, treatment, and rehabilitation of individuals affected by chronic brain injuries. Industry leaders and innovators are well-positioned to drive these transformative changes through collaborative efforts and cutting-edge research.

Future Market Insights’ analysis signals a new era of progress in neurological care, with promising advancements on the horizon that are set to reshape the landscape of chronic brain damage management.

Key Takeaways from the Market Study:

  • The Chronic Brain Damage Management market expanded at a CAGR of 3.5% from 2018 to 2022.
  • The market for managing chronic brain damage is anticipated to expand at a 7% CAGR from 2023 to 2033.
  • The market for managing chronic brain damage is anticipated to reach USD 1.77 billion by 2033.
  • The hospital sector holds the biggest market share, per the FMI research.
  • For the Chronic Brain Damage Management market, North America is predicted to have a 40% market share.
  • With a share of 20% throughout the projection period, it is expected that the East & South Asia market would grow considerably.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Chronic Brain Damage Management.” says an FMI analyst

Explore the High Demand for Chronic Brain Damage Management: Our Full Report Provides a Detailed Look at Emerging Trends!

Market Competition:

Key players in the market include companies such as NeuroVive Pharmaceutical AB, TEVA Pharmaceutical Industries Ltd., Integra LifeSciences Corporation, Medtronic PLC, Neuren Pharmaceuticals Ltd., Johnson & Johnson Services Inc., Smith & Nephew, Stryker, B.Braun Melsungen AG, Neural Analytics, Inc., along with healthcare providers and technology companies among other global players.

  • In August 2022, a study revealed that Abbott’s blood test for concussion has the potential to predict outcomes from brain injury and inform treatment interventions. The test measures levels of two biomarkers, Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin carboxy-terminal Hydrolase L1 (UCH-L1), in blood plasma within 24 hours of injury. High levels of GFAP and UCH-L1 were found to correlate with death and severe injury, and the test could accurately predict such outcomes six months after the injury. The study suggests that clinicians could use this test to get a more accurate picture of the severity of the injury and the expected course of recovery, enabling them to provide the best care for patients. Abbott is currently seeking FDA clearance for its TBI test on Alinity i and ARCHITECT core laboratory instruments, and the test is already CE Marked and available outside the U.S.

Key Segments Profiled in the Chronic Brain Damage Management Industry Survey:

Diagnosis:

  • Imaging studies
  • Blood tests
  • Brain evaluations

Treatment Type:

  • Occupational therapy
  • Physical therapy
  • Psychotherapy
  • Speech or language therapy

End- User:

  • Hospitals
  • Neurology Clinics
  • Independent Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Chiari Malformation Treatment Market Poised for Significant Growth, Reaching USD 4.2 Billion by 2033 registering a CAGR of 6.4%

According to a recent study conducted by Future Market Insights, the global chiari malformation treatment market, valued at USD 2.26 billion in 2023, is anticipated to witness substantial growth over the next decade. Projections suggest a robust Compound Annual Growth Rate (CAGR) of 6.4%, with the market expected to reach approximately USD 4.2 billion by 2033.

Chiari malformation, a condition characterized by the displacement of brain tissue into the spinal canal, has historically presented significant challenges in management. However, recent advancements in medical science have revolutionized the landscape of diagnosis and treatment. Enhanced diagnostic capabilities, driven by technological innovations, now facilitate earlier and more precise detection of Chiari malformation. This pivotal development enables healthcare providers to initiate timely interventions, thereby improving patient outcomes.

Surgical intervention remains a cornerstone of Chiari malformation treatment, particularly for patients exhibiting severe symptoms or complications. Among the surgical options, decompression surgery, which involves removing part of the skull to give more room to the cerebellum, is commonly pursued. Additionally, spinal fusion surgery is another therapeutic option available to stabilize the spine and prevent further damage, highlighting the surgical advancements contributing to market growth.

The report from Future Market Insights underscores a pivotal shift towards better diagnostic and treatment approaches, which not only promise improved patient outcomes but also drive market expansion. As awareness and technology continue to advance, the Chiari malformation treatment market is set for significant expansion in the coming years.

Healthcare providers, patients, and stakeholders in the medical community are encouraged to stay informed about the developments in this field, as ongoing innovations and the introduction of new treatment modalities are expected to further enhance patient care and market growth.

Key Takeaways from the Market Study:

  • The Chiari malformation treatment market is expected to grow at a value of 6.4% CAGR in the forecast period 2023-2033
  • By treatment, surgical treatment is expected to possess 60% market share for Chiari malformation treatment market in 2023.
  • Europe is expected to possess 40% market share for Chiari malformation treatment market in 2023.
  • North America is expected to possess 45% market share for Chiari malformation treatment market in 2023.

“Ongoing research into the use of non-invasive techniques such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) are expected to improve symptoms of Chiari Malformation. This, in turn, will drive the growth of the market.” states an FMI analyst

Rising Interest in Market Trends: Our Detailed Report Provides Essential Insights!

Competitive Landscape:

Key players in the Chiari malformation treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Mylan N.V., Hikma Pharmaceuticals PLC, Novartis AG, Fresenius Kabi AG, Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, Bayer AG, Sun Pharmaceutical Industries Ltd

  • Mylan’s generic version of the pain medication gabapentin has been approved by the US Food and Drug Administration (FDA) to treat neuropathic pain, which can be a symptom of Chiari Malformation.
  • Hikma’s generic version of the pain medication gabapentin has been approved by the US Food and Drug Administration (FDA) to treat neuropathic pain, which can be a symptom of Chiari Malformation

Key Segments Profiled in the Chiari Malformation Treatment Market Survey:

Type:

  • Type 1
  • Type 2
  • Type 3
  • Type 4

Treatment:

  • Medical Treatment
  • Surgical Treatment

Diagnosis:

  • MRI
  • Cine MRI
  • X-rays
  • CT-Scan

End User:

  • Hospitals
  • Surgical Centres
  • Research Institutes
  • Specialty Clinics

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Hydration Boosters Market Shaping the Future of Functional Beverages and Supplements

According to a recent industry analysis conducted by Future Market Insights, Inc., a leading market research and competitive intelligence provider, global hydration boosters market is projected to grow significantly, with an estimated valuation of USD 8.8 billion in 2024 and a forecasted rise to USD 19.5 billion by 2034, driven by a CAGR of 8.3% over the period. This growth is fueled by changing consumer preferences, a focus on health-conscious products, and innovative marketing strategies, such as influencer partnerships and social media campaigns.

Key industry trends include the increasing popularity of calorie- and sugar-free hydration solutions, particularly flavored options like apple, citrus, and watermelon, which enhance both taste and health benefits. The market is also benefiting from the demand for convenient, portable product formats, such as powdered solutions, liquid concentrates, and single-serving packets, which cater to busy consumers and athletes.

“Analyze the projected growth of the global hydration boosters market, focusing on the impact of innovative product development, changing consumer preferences, and the increasing demand for sugar-free and calorie-free options on the market’s CAGR of 8.3% over the 2024-2034 period.”- says Nandini Roy Choudhury, Client Partner at Future Market Insights 

The sector is evolving with the introduction of multifunctional hydration products that support energy boosts, immune health, and skin wellness, incorporating ingredients like collagen, caffeine, and vitamins. The rising consumer interest in holistic wellness is driving the popularity of these products.

As global temperatures rise and active lifestyles become more common, the need for effective hydration solutions is growing, particularly in regions like the U.S., Germany, and India. In the U.S., for example, the market is expected to reach USD 3.4 billion by 2034, driven by trends in fitness and preventive healthcare. Germany is also seeing increased demand for hydration products, particularly among its elderly population.

Competition Outlook

The global business landscape of hydration relief products revolves around the rising consumer appetite, the trend of preventive healthcare, and product innovation. Attractive packaging, the infusion of natural healthy ingredients, and the widespread distribution network attract companies to increase their market share.

These strategies are not only helping the companies to increase their revenue but also increasing their consumer base and brand attraction among consumers. Key companies in the global industry are narrowing down their product strategy by including clean-label solutions in their portfolio to attract health-conscious consumers. These companies emphasize sustainability and infuse unique ingredient formulations into their products.

These marketing strategies and product innovations help the key players to increase their sales across the globe. Increasing investment in research and development and widespread online distribution attract manufacturers and brands to increase their sales in the global industry. Companies are coming up with different solutions for different applications to gain consumer attraction.

For Instance

  • In October 2023 BODYARMOR Sports Nutrition company launched the “Bodyarmor Flash I.V.” in powder and bar form in the rapid rehydration category. According to the company, this product with added minerals and vitamins will help the consumers to stay hydrated.
  • In April 2024, Evocus company launched the four popular flavors of the products to keep them competitive in the global business landscape.

Leading Manufacturers

  • MOONFREEZE FOODS PRIVATE LIMITED
  • SEEverse
  • HydroMate
  • Liquid I.V.
  • Espri Life
  • Venture Pal
  • Drip Drop Hydration Inc
  • EVLUTION NUTRITION
  • Adapted Nutrition
  • Hydralyte
  • Equalan Pharma
  • OFFSPRING BEAUTY CO
  • Lipoid-Kosmetik

Key Segments of the Report

By Product Type:

Key product types like Powdered Hydration boosters, Liquid Concentrates, Hydration Gels, and Serum are included in the report

By Flavor:

Key flavors like Watermelon, Citrus, Green Apple, Berries, and others are considered in the report.

By End Use:

This segment has been categorized into Improve Hydration, Skin Health, Energy Boost, Immune Support, and others.

By Sales Channel:

Industry analysis has been carried out in different sales channels as store-based retailing (Supermarkets/Hypermarkets, Departmental Stores, Convenience Stores, Other Sales Channel) and online retailing (Company Website, E-commerce Platform).

By Region:

Industry analysis has been carried out in key countries of North America, Latin America, Europe, Middle East and Africa, East Asia, South Asia, and Oceania

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube